Our top pick for
Building a portfolio
G1 Therapeutics, Inc is a biotechnology business based in the US. G1 Therapeutics shares (GTHX) are listed on the NASDAQ and all prices are listed in US Dollars. G1 Therapeutics employs 122 staff and has a trailing 12-month revenue of around USD$45.3 million.
|52-week range||USD$10.81 - USD$37.069|
|50-day moving average||USD$23.256|
|200-day moving average||USD$18.7998|
|Wall St. target price||USD$59|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.703|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$45.3 million|
|Gross profit TTM||USD$45.3 million|
|Return on assets TTM||-23.49%|
|Return on equity TTM||-45.86%|
|Market capitalisation||USD$1.1 billion|
TTM: trailing 12 months
There are currently 7.7 million G1 Therapeutics shares held short by investors – that's known as G1 Therapeutics's "short interest". This figure is 21% up from 6.3 million last month.
There are a few different ways that this level of interest in shorting G1 Therapeutics shares can be evaluated.
G1 Therapeutics's "short interest ratio" (SIR) is the quantity of G1 Therapeutics shares currently shorted divided by the average quantity of G1 Therapeutics shares traded daily (recently around 2.2 million). G1 Therapeutics's SIR currently stands at 3.45. In other words for every 100,000 G1 Therapeutics shares traded daily on the market, roughly 3450 shares are currently held short.
However G1 Therapeutics's short interest can also be evaluated against the total number of G1 Therapeutics shares, or, against the total number of tradable G1 Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case G1 Therapeutics's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 G1 Therapeutics shares in existence, roughly 180 shares are currently held short) or 0.2816% of the tradable shares (for every 100,000 tradable G1 Therapeutics shares, roughly 282 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against G1 Therapeutics.
Find out more about how you can short G1 Therapeutics stock.
We're not expecting G1 Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, G1 Therapeutics's shares have ranged in value from as little as $10.81 up to $37.069. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while G1 Therapeutics's is 2.3272. This would suggest that G1 Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.